NetraMark Holdings Inc AIAI

NetraAI’s biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset testedThe study showed improved performance across conventional machine learning, neural-network and foundation-model (including Fable 5) approaches in schizophrenia, major depressive disorder and pancreatic cancerFindings support what the company believes is the potential of an unbiased discovery-first approach to uncover clinically relevant structure in c

Veteran global finance leader adds institutional investment, capital markets and strategic transaction expertise to NetraMark TORONTO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Kevin Felix as Strategic Advisor, strengthening the senior strateg

Virtual corporate presentation available September 11, 2026NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28t

Company highlights growing contracted project activity, expanding pharmaceutical engagements, initial commercial activation of CRO channel and continued scientific progressTORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strate

Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platformTORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged AM Public Relations (AM PR), a healthcare-focused public relations agency

New agreement is a significant commercial milestone and the Company’s first with its contract research organization partnerAgreement expands NetraMark’s portfolio of AI-driven projects in central nervous system (CNS) disorders TORONTO, July 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today anno

This agreement represents NetraMark's ninth commercial contract since the start of its current fiscal year and demonstrates growing interest in AI-enabled clinical trial analytics, like NetraAI, among biopharmaceutical companies. TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmac

NEW YORK, NY / ACCESS Newswire / June 16, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Virtual Investor Conference taking place Wednesday and Thursday, ...

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET. Interested parties can access the live presentation through t

By M. Marin OTCQB: AINMF READ THE FULL AINMF RESEARCH REPORT AINMF believes platform is well-positioned, as use of AI in clinical development is expected to rise NetraMark (OTCQB: AINMF), an AI company developing AI and Machine Learning (ML) solutions to help optimize pharmaceutical clinical research trial activities, AINMF believes its NetraAI platform is well-positioned to support the next-gen

Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service of CDS Clearing and Depository Services Inc.Company NameRecord DateMeeting DateType Apex Critical Metals Corp. June 8, 2026July 10, 2026AG Ashley Gold Corp. June 9, 2026July 14, 2026AS Athena Gold Corporation June 9, 2026July 24, 2026AS CORE SILVER CORP. *May 12, 2026June 16,...

Company to participate in plenary panel on artificial intelligence in psychiatry and present two scientific posters highlighting explainable AI applications in precision psychiatryTORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments. During the second quarter, NetraMark continued to

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Lawrence Guy has resigned from the Company’s Board of Directors, effective May 7, 2026, for personal reasons. The Board and management of NetraMark thank Mr. Guy for his service and contributio

TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, as Fractional Chief Medical Officer, marking an important step in the Company’s evolution as it advances toward broader globa

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced that senior management will open the market at the Toronto Stock Exchange on May 5, 2026. The market open ceremony follows a period of sustained momentum as NetraMark continues to advance its proprietary NetraAI platform